Clinical evidence indicates that mutation/activation of EGF receptors (EGFRs) is mutually exclusive with the presence of K-RAS oncogenes in lung and colon tumors. We have validated these observations using genetically engineered mouse models. However, development of pancreatic ductal adenocarcinomas driven by K-Ras oncogenes are totally dependent on EGFR signaling. Similar results were obtained using human pancreatic tumor cell lines. EGFRs were also essential even in the context of pancreatic injury and absence of p16Ink4a/p19Arf. Only loss of p53 made pancreatic tumors independent of EGFR signaling. Additional inhibition of PI3K and STAT3 effectively prevented proliferation of explants derived from these p53-defective pancreatic tumors. These findings may provide the bases for more rational approaches to treat pancreatic tumors in the clinic.
INTRODUCTION
Patients with pancreatic ductal adenocarcinoma (PDAC) have an average survival of less than a year with fewer than 5% surviving more than 5 years (Vincent et al., 2011) . Current standard of care for PDAC patients is Gemcitabine, a nucleoside analog that only prolongs survival for few weeks (Burris et al., 1997; Li et al., 2004) . Hence, there is an urgent medical need to find more effective therapeutic approaches to treat this deadly disease (Hidalgo, 2010) .
PDAC is likely to stem from a process known as acinar to ductal metaplasia that involves either transdifferentiation of adult acinar cells or misdifferentiation of their progenitors into ductal-like cells. These cells can subsequently progress into malignant adenocarcinoma through a series of histopathological lesions known as pancreatic intraepithelial neoplasias (PanINs) (Maitra and Hruban, 2008) . Early pancreatic lesions including low-grade PanINs already carry mutations in K-RAS oncogenes, along with loss or inactivation of the P16INK4a tumor suppressor (Kanda et al., 2012) . High-grade lesions develop upon accumulation of further mutational events, mainly involving inactivation of other tumor suppressors such as TP53, SMAD4, or BRCA2 (Hong et al., 2011) . Exome sequencing analysis of PDAC genomes has revealed an incredibly complex pattern of mutations affecting as many as 12 different signaling pathways (Jones et al., 2008) . In a recent study describing the exomic sequence of different areas of a single PDAC tumor, Campbell et al. (2010) have illustrated the perverse molecular evolution of these tumors even before they spread to other organs.
In 2007, a clinical trial combining Gemcitabine with the EGFR inhibitor, Erlotinib, reported some responses in a limited number of PDAC patients (Moore et al., 2007 ). Yet, the overall results were not sufficiently significant for the FDA to recommend the Significance Previous clinical studies have suggested a therapeutic benefit of Erlotinib, an EGFR inhibitor, in pancreatic ductal adenocarcinoma patients. Here, we show that these observations may have a mechanistic base. EGFRs are expressed during pancreatic injury and in preneoplastic PanIN lesions. Loss of p53, but not of p16INK4a/p19ARF tumor suppressors, relieved the need of tumor cells to maintain EGFR signaling. Yet, loss of EGFRs increased tumor latency and survival. Tumor explants lacking p53 and EGFRs were sensitive to the combined inhibition of PI3K and STAT3. Thus, successful treatment of advanced human pancreatic tumors may require inhibition of at least four distinct signaling cascades including those driven by K-RAS, EGFRs, PI3K, and STAT3.
combination of these two drugs as standard of care. These observations are intriguing because the EGFR is known to signal upstream of K-RAS and hence, its inhibition should have little or no effect on downstream K-RAS-driven oncogenic signals (Yarden and Sliwkowski, 2001) . Indeed, in nonsmall lung adenocarcinoma (NSCLC) mutations in EGFR and in K-RAS are mutually exclusive (Shigematsu et al., 2005) . Likewise, a large clinical trial carried out in patients with advanced colorectal carcinomas (CRC) has determined that patients carrying tumors with K-RAS mutations do not benefit from treatment with Cetuximab, a monoclonal antibody that blocks EGFR signaling (Karapetis et al., 2008) . In spite of these odds, we decided to interrogate by genetic means whether EGFRs might play a role in K-Ras oncogene-driven PDAC using a well-characterized genetically engineered mouse (GEM) model for this disease (Guerra et al., 2007 (Guerra et al., , 2011 .
RESULTS

Acinar to Ductal Metaplasia Requires EGFR Signaling Even in the Presence of K-Ras Oncogenes
Pancreatic acinar to ductal metaplasia is a precursor of the preneoplastic PanIN lesions that eventually lead to PDAC development (Parsa et al., 1985) . In normal mice, generation of acinar to ductal metaplasia is largely dependent on activation of EGFRs (Means et al., 2005) . Because EGFRs signal through the Ras pathway, we examined whether expression of a constitutive active K-Ras oncoprotein could bypass the requirement for EGFR activity during the generation of metaplasia. Pancreatic cell explants obtained from K-Ras +/LSLG12Vgeo ;Elas-tTA/tetOCre mice (from now on ElasK-Ras G12V ) in which the K-Ras G12V oncogene is selectively expressed in acinar cells, efficiently transdifferentiated into metaplastic ductal-like cells leading to the generation of 5-to 10-fold more metaplastic structures than those not expressing the oncogene ( Figure S1A available online). Yet, K-Ras G12V -driven metaplasia was still largely dependent on activation of EGFRs because addition of their cognate ligands EGF or TGFa, effectively increased the number of metaplastic figures ( Figure S1B ). Ablation of Egfr alleles significantly reduced, but did not eliminate the ability of acinar cell explants to generate metaplastic structures (Figures S1B-S1D). These observations suggest that EGF and TGFa may contribute to acinar to ductal metaplasia by activating additional receptors, at least in vitro. Pancreatic acinar cells also expressed high levels of amphiregulin, but not of other members of the EGFR family of ligands ( Figure S1E ).
Human and Mouse Pancreatic Lesions Express Abundant EGFRs
Mouse acinar cells did not express detectable levels of EGFRs regardless of whether they expressed a K-Ras oncogene or not ( Figure 1A ). In contrast, PanINs, regardless of their grade, were decorated with high levels of the receptor ( Figure 1A ) (Ueda et al., 2004; Hingorani et al., 2005) . Elevated expression of EGFRs was maintained during tumor progression including well-differentiated glandular structures within PDAC tumors (Figure 1A) . However, expression levels decreased in poorly differentiated tumor cells ( Figure 1B ) (Ueda et al., 2004; Hingorani et al., 2005) . Human normal pancreata also displayed undetectable levels of EGFRs ( Figure 1C ). However, morphologically normal acinar cells of pancreatitis patients expressed significant levels of EGFRs in a manner highly reminiscent of the result obtained in pancreata derived from mice exposed to caerulein ( Figures 1B and 1C ). These observations are in agreement with an early study describing overexpression of EGFRs in patients with chronic pancreatitis (Korc et al., 1994) . We also observed that metaplasias present in pancreatitis biopsies displayed elevated levels of EGFRs ( Figure 1C ). Low-grade and high-grade PanINs present in human PDAC tumors also expressed high levels of EGFRs ( Figure 1C ). Interestingly, their pattern of expression in tumored areas closely resembled that observed in mouse PDACs ( Figure 1B ). Whereas well-differentiated tumor glands were uniformly decorated with EGFR antibodies, less-differentiated glands expressed significantly lower levels of the receptors ( Figure 1C ). Finally, metastatic cells localized in a regional lymph node retained detectable, albeit somewhat attenuated levels of EGFRs ( Figure 1C ). These observations indicate that induction of EGFRs in acinar cells of injured pancreata as well as in PanIN and PDAC lesions is a common event in mouse and human pancreatic tissues.
EGFRs Are Essential for the Generation of K-Ras Oncogene-Driven PanIN Lesions
To determine whether development of PanIN lesions and PDAC tumors require EGFR signaling, we generated ElasK-Ras
G12V
; Egfr +/+ and ElasK-Ras G12V ; Egfr lox/lox strains and analyzed their pancreata at 1 year of age. These mice were not exposed to doxycycline to allow expression of the Elastase-driven Cre recombinase during late embryonic development (E16.5). Cremediated recombination allowed concomitant expression of the resident K-Ras G12V oncogene and ablation of the floxed Egfr alleles in acinar cells ( Figure S2A ). As illustrated in Figure 2A , control ElasK-Ras
;Egfr +/+ littermates (12 out of 13 animals, 92%) exhibited abundant low-and high-grade PanIN lesions (average of 16 and 5 lesions per pancreata, respectively). Moreover, three animals (23%) displayed sizable PDAC tumors. Animals heterozygous for the Egfr locus also harbored lowand high-grade PanIN lesions albeit at reduced numbers (average of 5 and 2.5 lesions per pancreata, respectively). Likewise, only one out of ten heterozygous mice carried a PDAC tumor (Figure 2A ).
In contrast, careful analysis of serial sections of pancreata from 1-year-old ElasK-Ras G12V ; Egfr lox/lox animals (n = 24) only revealed the presence of a limited number of PanIN lesions (ten low-grade and two high-grade PanINs) in eight mice. More importantly, all of these lesions expressed EGFRs due to incomplete recombination of the floxed Egfr alleles (Figures S2B and S2C) . Similar results were obtained in older mice sacrificed at 2 years of age (data not shown). These observations indicate that EGFRs are essential for the induction of PanINs and PDAC by K-Ras oncogenes.
Adult Mice Also Require EGFR Signaling for PDAC Development To exclude the possibility that these observations were due to developmental defects in acinar cells lacking EGFRs during embryonic development, we exposed ElasK-Ras G12V ;Egfr and ElasK-Ras G12V ;Egfr lox/lox littermates to doxycycline from conception until adulthood (8 weeks of age) to prevent expression of the Cre recombinase. As previously reported, induction of PanIN lesions in these mice requires a pancreatic insult (Guerra et al., 2007) . Analysis of 14-month-old ElasK-Ras G12V ;
Egfr lox/lox mice (n = 14) treated with caerulein for 3 months (P90-P180), that is, 1 year after turning on expression of the resident K-Ras G12V oncogene, revealed complete absence of EGFR positive low-and high-grade PanIN lesions or PDAC tumors (Figure 2B) . Only three mice carried PanIN lesions, all of which expressed EGFRs (data not shown). Mice examined at 2 years of age displayed a total of nine low-grade and three high-grade PanIN lesions in three out of the seven mice analyzed, all of which retained EGFR expression (data not shown).
As summarized in Figure 2B , control ElasK-Ras
;Egfr Figure S1 .
et al., 2011). All mice (n = 13) developed low-grade PanINs (average of 18 lesions per pancreata) and more than 90% (12 out of 13) displayed high-grade PanINs (average of 16 lesions per pancreata). Only one mouse out of 13 (8%) had a full-blown PDAC tumor ( Figure 2B ). Ablation of a single Egfr allele yielded similar results regarding the number of mice affected (80% of the animals carried PanIN lesions and 10% a PDAC tumor). However, the average number of lesions per pancreata was significantly lower ( Figure 2B ). These observations strongly support the concept that initiation of PDAC tumors requires at least two independent signaling inputs mediated by the EGFR and the K-Ras oncoprotein.
EGFRs Cooperate with Resident K-Ras Oncogenes by Activating AKT and STAT3 Signaling Pathways In an attempt to shed light on the mechanism by which the EGFR cooperate with the resident K-Ras G12V oncoprotein to induce pancreatic lesions, we examined the status of AKT, a well-known downstream effector of the PI3K/AKT survival pathway and STAT3, a mediator of inflammatory cytokines that has been recently implicated in PDAC development (Corcoran et al., 2011; Fukuda et al., 2011; Lesina et al., 2011) . As illustrated in Figure S2D , pancreata of untreated ElasK-Ras G12V mice display acinar cells that do not express either EGFR or detectable levels
Cancer Cell EGFR Signaling Is Essential for Pancreatic Cancer of phosphorylated AKT or STAT3. Thus indicating that expression of the resident K-Ras G12V oncoprotein does not activate these pathways, at least in this cellular context. In contrast, pancreata of ElasK-Ras G12V mice treated with caerulein for 3 months exhibit uniform expression of EGFRs along with nuclear phospho-AKT and phospho-STAT3 proteins through the entire pancreas. Since K-Ras G12V expression in these mice only takes place in about 30% of their acinar cells, activation of the EGFR/AKT/STAT3 axis must be independent of K-Ras oncogene signaling (Guerra et al., 2007 (Guerra et al., , 2011 . As expected, pancreatic lesions including metaplasias and PanINs, also display activated phospho-AKT and phophop-STAT3 molecules in response to EGFR expression, suggesting that activation of the PI3K/AKT and STAT3 signaling pathways play a role in the induction of these lesions ( Figure S2E ). Finally, the presence of nuclear phospho-AKT and 
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phospho-STAT3 in PDAC tumors also suggests that activation of these effector molecules might be required for tumor progression (data not shown).
Human Pancreatic Ductal Tumor Cell Lines Are Dependent on EGFR Signaling Regardless of the Presence of K-RAS Oncogenes
Next, we interrogated whether cell lines derived from human PDACs also depend on EGFR signaling for proliferation. We selected eight well-characterized tumor cell lines with different pattern of mutations. Six of them, AsPc1, CFPAC, IMIMPC-2, MIAPaCa, PANC1, and SKPC, harbor K-RAS oncogenes along with inactivation of P16INK4a and TP53 tumors suppressor genes (Table 1) . CFPAC and SKPC cells also have a deleted SMAD4 locus. The remaining pancreatic tumor cell lines BxPc3 and T3M4, carry a wild-type K-RAS locus. Yet, they also have mutated or silenced P16INK4a and TP53 loci and one of them, BxPc3, a mutated SMAD4 locus (Table 1) . Knockdown of EGFRs using two independent shRNAs efficiently inhibited proliferation (>70%) of AsPc1, BxPc3, MIAPaCa, and T3M4 cells. Two cell lines, PANC1 and IMIMPC-2, were only partially inhibited whereas the remaining cell lines, CFPAC and SKPC, were resistant (Table 1) . Thus, the effect of EGFR signaling on proliferation appears to be independent of the presence of K-RAS oncogenes. Knockdown of EGFR expression only inhibited the PI3K pathway, as determined by phosphorylation of AKT, in those cells carrying a wild-type K-RAS locus ( Figure S3 ).
Five of these tumor cell lines, including K-RAS oncogenepositive CFPAC, MiaPaCa and SKPC cells, and K-RAS oncogene-negative BxPc3 and T3M4 cells were partially sensitive to Erlotinib (Table 1) . Erlotinib treatment did not result in complete inhibition of cell proliferation (IC 90 ) even at concentrations as high as 200 mM. The SKPC cell line, whereas partially sensitive to Erlotinib, was refractory to EGFR knockdown (Table  1) . This discrepancy might be explained by either the inability of the shRNAs to effectively knockdown the high levels of EGFRs present in this cell line or to the off-target effect of Erlotinib on related tyrosine protein kinase receptors ( Figure S3 ). We also examined the effect of directly inhibiting the RAS pathway by using the MEK inhibitor, PD325901. Four cell lines carrying K-RAS oncogenes, CFPAC, IMIMPC-2, MiaPaCa, and SKPC cells were sensitive to this inhibitor. Interestingly, the BxPc3 and T3M4 cell lines that have a wild-type K-RAS locus, were also highly sensitive to the MEK inhibitor, suggesting that these cells may have activated their RAS pathway by mechanisms other than mutating their K-RAS locus (Table 1) . Finally, AsPc1 and PANC1 cells were resistant to MEK inhibition in spite of carrying K-RAS oncogenes, suggesting that in these cells K-RAS oncogenes may no longer play an essential role in maintaining their proliferative properties (Table 1) .
K-RAS G12V -Driven Lung and Intestinal Tumors Do Not Require EGFR Signaling
The above results, taken together, indicate that proliferation of pancreatic ductal tumor cells have a dual requirement for EGFR and K-RAS signaling. These observations are at odds with extensive clinical data in human NSCLCs, in which oncogenic mutations in the EGFR and K-RAS loci are mutually exclusive (Shigematsu et al., 2005) . Likewise, CRC patients carrying K-RAS oncogenes do not benefit from treatments involving inhibition of EGFR signaling (Karapetis et al., 2008) . To determine whether the results described above only occur in the context of mouse tumor models or are an intrinsic property of pancreatic tumors, we ablated the Egfr locus in two well-characterized GEM models of lung and intestinal tumors induced by the same endogenous K-Ras G12V oncogene used to initiate pancreatic lesions. In these models, expression of the resident K-Ras G12V oncogene is mediated by activation of an ubiquitously expressed
Cre-ERT2 inducible recombinase knocked-in at the locus encoding the large subunit of RNA polymerase II (RERT strain; see Guerra et al., 2003) . For the lung model, RERT;K-Ras G12V ;
Egfr +/+ (n = 17), RERT;K-Ras G12V ;Egfr +/lox (n = 13), and RERT; K-Ras G12V ;Egfr lox/lox (n = 25) littermates were treated at weaning with a single dose of 4-hydroxy-tamoxifen (4OHT) (Guerra et al., 2003; Puyol et al., 2010) . As illustrated in Figure 3A , RERT;K-Ras G12V ;Apc lox/lox ;Egfr +/+ (n = 7) littermates were treated at weaning for 2 weeks (3 days per week) with 4OHT. These mice displayed similar tumor burden including adenomas and adenocarcinomas (data not shown) and did not survive beyond 20 weeks of age ( Figure 3C ). As expected, tumor cells, regardless of genotype, failed to express EGFRs ( Figure 3D ). These results, taken together, indicate that the requirement of EGFR signaling for the onset of neoplastic pancreatic lesions driven by K-Ras oncogenes is unique to this tumor type. Moreover, the similarity between the results obtained in clinical trials and in mouse models of lung and intestinal cancer reinforces the concept that GEM tumor models faithfully reproduce those events observed in cancer patients.
Loss of Senescence Does Not Override the Need for EGFR Signaling during PanIN and PDAC Development
The EGFR is known to promote survival signals that might be essential to overcome the oncogene-induced senescence characteristic of the early stages of pancreatic tumor development (Collado et al., 2005; Guerra et al., 2011) . Indeed, most human PDACs carry a mutated or silenced P16INK4a/P14ARF locus, an event likely to override senescence (Hong et al., 2011) . Thus, we reasoned that ablation of the p16INK4A/ p19ARF tumor suppressors (from now on p16/p19), might bypass the requirement for EGFR signaling during tumor and their pancreata examined at 16 weeks of age, before they displayed any obvious signs of overt tumor development. These mice were not exposed to doxycycline to allow expression of the resident K-Ras G12V oncogene during late embryonic development (Guerra et al., 2007) . As summarized in Figure 4A , six out of eight mice carrying wild-type EGFRs displayed abundant low-and high-grade lesions. Moreover, five animals had developed at least a PDAC tumor at this time. In contrast, none of the mice carrying Egfr lox/lox alleles (n = 6) displayed PanIN lesions or PDAC ( Figure 4A) .
Mice with the above genotypes were allowed to age. Littermates carrying wild-type Egfr alleles, either in homozygocity (n = 12) or heterozygocity (n = 30) succumbed to the disease before they reached 10 months of age ( Figure 4B ). Postmortem analysis revealed multiple lesions including invasive and metastatic PDAC as well as anaplastic carcinomas that metastasized to multiple organs (Aguirre et al., 2003; Guerra et al., 2011) . As expected, none of the low-grade PanIN lesions contained senescent cells as determined by staining for b-galactosidase activity (data not shown). In contrast, ElasKRas G12V ;p16/p19 lox/lox ;Egfr lox/lox mice (n = 7) sacrificed at 1 year of age did not carry any PanIN lesion positive for EGFRs in spite of careful analysis of multiple serial sections (data not shown). Only four animals had a total of six low-grade and two high-grade PanIN ''escaper'' lesions positive for EGFRs ( Figure 4C ). Seventeen additional ElasK-Ras
G12V
;p16/p19 lox/lox ; Egfr lox/lox mice were allowed to age beyond 1 year. All of them remained in good health condition at 80 weeks of age ( Figure 4B ). Histological examination of their pancreata at this time did not reveal any lesions (data not shown). These observations indicate that abrogation of senescence by inactivation of the p16/p19 tumor suppressors does not relieve pancreatic tumor cells of their need for EGFR signaling.
Loss of p16/p19 tumor suppressors also accelerates tumor development in adult mice providing they have undergone chronic or temporary pancreatitis (Guerra et al., 2011 signaling during PanIN and PDAC development cannot be compensated by loss of the p16/p19 tumor suppressors even in the context of an inflammatory response induced by pancreatitis.
Loss of p53 Triggers Oncogenic Pathways Independent of EGFR Signaling
Human PDAC tumors harbor mutations in classical tumor suppressor genes such as TP53, SMAD4, or BRCA2 (Hong et al., 2011) . Likewise, mice expressing an endogenous K-Ras oncogene during embryonic development in the absence of a functional p53 protein develop aggressive PanINs and PDAC tumors that result in the death of the animals within their first 4 to 5 months of life (Hingorani et al., 2005; Guerra et al., 2007) . Similar results have been obtained in the context of adult K-Ras oncogene expression followed by pancreatic damage (Guerra et al., 2011) . To examine the effect of abrogating EGFR signaling in the absence of p53, we inserted conditional p53 lox alleles in the ElasK-Ras G12V strain in the presence of wild-type or floxed Egfr alleles. Animals were sacrificed at 10 weeks of age before they showed signs of overt tumor development. As summarized in Figure 5A , control mice carrying wild-type Egfr alleles (n = 7) displayed abundant low-and high-grade lesions and PDAC, averaging ten high grade PanINs and four PDAC tumors per mouse. Interestingly, mice carrying conditional Egfr alleles (n = 5) also displayed neoplastic lesions but with reduced incidence ( Figure 5A ).
When we allowed these mice to age, all animals carrying wild-type Egfr alleles (n = 10) succumbed to pancreatic tumors around 20 weeks of age with a median survival of 12 weeks ( Figure 5B ). Similar results were obtained with heterozygous mice (n = 13) ( Figure 5B ). At the time of death or humane end point, these mice displayed multiple PanIN lesions and PDAC tumors including a lung metastasis in one of the animals.
ElasK-Ras
G12V ;p53 lox/lox ;Egfr lox/lox mice (n = 13) also developed low-and high-grade PanINs as well as PDAC tumors (Figure 5B) . Moreover, three of these mice also had macroscopic metastasis at different locations such as peritoneum, diaphragm, liver, and lung (data not shown). However, mice in which the conditional Egfr alleles have been ablated died by 40 weeks of age and displayed a median survival 83% longer than that of littermates expressing EGFRs (22 versus 12 weeks) ( Figure 5B ). Similar results were obtained with mice that expressed the resident K-Ras G12V oncogene during adulthood and were treated for 3 months with caerulein. Whereas ElasK-Ras G12V ;p53 lox/lox ;Egfr lox/lox animals (n = 26) died before reaching 60 weeks of age with a median survival of 38 weeks, control ElasK-Ras G12V ;p53 lox/lox ;Egfr +/lox mice (n = 8) were dead at 35 weeks of age with a median survival of 27 weeks (data not shown). Thus, ablation of EGFR signaling resulted in an increased survival time of 40%.
Tumor development in mice carrying conditional Egfr alleles was not due to incomplete recombination because the large majority of the PanIN lesions and PDAC tumors did not express EGFRs when analyzed by IHC ( Figure S4A) . Moreover, PCR analysis of DNA isolated from tumor cells also failed to reveal unrecombined Egfr lox alleles in most lesions (data not shown).
Finally, histopathological analysis of PanIN and PDAC tumors lacking p53 and EGFRs did not reveal significant differences with those present in control animals ( Figure S4A ). These observations, taken together, indicate that loss of p53 activates oncogenic pathways that bypass the requirement of EGFR signaling for tumor development. with either vehicle or Erlotinib (100 mg/Kg) for 4 weeks. A small group of mice (n = 3) analyzed at the start of the treatment revealed low-and high-grade PanINs in each of the animals. Moreover, two of the mice already carried small PDACs ( Figure S4B ). At the end of the 4-week treatment, all mice that received vehicle (n = 7) displayed a significant increase in the number of lesions ( Figure 5C ). In contrast, Erlotinib treatment led to disappearance of all lesions in three out of the 14 animals included in this cohort. Moreover, three additional Erlotinib-treated mice contained PanIN lesions but no PDAC tumors ( Figure 5C ). Overall, the Erlotinib-treated cohort had fewer lesions than the control group, indicating a limited but reproducible therapeutic effect of this EGFR inhibitor on PDAC development ( Figure 5C ). IHC analysis of lesions in mice treated with Erlotinib for 4 weeks revealed robust inhibition of pAKT but not of pSTAT3 or pERK when compared with samples obtained from control mice treated with vehicle ( Figure S4C ). As an additional control, we examined the status of pAKT, pSTAT3 and pERK in ElasKRas G12V ;p53 lox/lox mice carrying either wild-type or conditional Egfr alleles. As expected, ablation of EGFR expression resulted in inhibition of pAKT but not of pSTAT3 or pERK ( Figure S4D ). Interestingly, full blown PDACs retained pAKT IHC ( Figure S4E ), a result confirmed by western blot analysis ( Figure S5 and data not shown). These observations suggest that loss of p53 might activate the PI3K pathway by a mechanism independent of EGFR signaling.
EGFR Signaling Is Required for Proliferation of PDAC Tumor Cell Explants
Knockdown of EGFR expression effectively slowed proliferation of cell explants derived from PDAC tumors isolated from ElasK-Ras G12V mice ( Figure 6A ). Similar results were obtained using explants from tumors obtained from ElasK-Ras G12V ;p16/ p19 lox/lox and ElasK-Ras G12V ;p53 lox/lox animals ( Figure 6A ).
These tumor explants, regardless of genotype, were also sensitive to Erlotinib ( Figure 6B ). As expected, Erlotinib had a cytostatic effect because inhibition required continuous exposure to the drug (data not shown). Knockdown of EGFRs in these tumor explants significantly inhibited phosphorylation of STAT3 ( Figure S5 ). Phosphorylation of ERK proteins was also ameliorated by EGFR knockdown ( Figure S5 ), possibly an indirect consequence of the limited proliferation of these cells in the absence of EGFRs ( Figure 6A ). Interestingly, phosphorylation of AKT, a marker for the activation of the PI3K/AKT survival pathway was downregulated in all explants except in those lacking p53 ( Figure S5 ).
Cooperation between PI3K and STAT3 Signaling Pathways in the Absence of EGFRs
We reasoned that availability of mouse PDAC tumor explants lacking EGFRs and p53 may allow us to identify additional signaling pathways that contribute to tumor development. Cancer Cell
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Unexpectedly, Erlotinib partially inhibited proliferation of PDAC explants from ElasK-Ras G12V ;p53 lox/lox ;Egfr lox/lox mice. These results are most likely due to off-target effects because shRNAs against the Egfr locus did not have any inhibitory effect on the proliferation rate of these cells ( Figures 6A and 6B ). As illustrated in Figure 7 , inhibition of PI3K with ETP-46992 (Martínez Gonzá lez et al., 2012) a selective inhibitor for the p110a and d catalytic subunits only induced partial inhibition ( Figure S6 ). However, combination of this inhibitor with Erlotinib resulted in robust inhibition of these tumor cell explants even in the absence of EGFRs and p53 ( Figure 7 ). As indicated above, ablation or inhibition of EGFRs in ElasKRas G12V ;p53 lox/lox mice blocked AKT but not STAT3 phosphorylation ( Figures S4C and S4D) . Interestingly, knockdown of STAT3 expression did not inhibit proliferation of tumor cell explants, regardless of their genotype. However, addition of the PI3K inhibitor to the Stat3 shRNA robustly inhibited proliferation of all tumor cell explants (Figure 7 ). These observations indicate that the STAT3 pathway also contributes to tumor development at least in the absence of p53. Moreover, in this context, PI3K may signal by pathways independent of AKT (Vogt and Hart, 2011) . Thus, successful treatment of PDAC tumors in the clinic may require compound inhibition of at least four distinct signaling cascades including those driven by K-RAS, EGFR, PI3K, and STAT3. Figure S5 .
vations in NSCLCs, a tumor type that present frequent mutations in both EGFR and K-RAS, have indicated that they are mutually exclusive (Shigematsu et al., 2005) . Similar results have been obtained in CRC patients. According to a large clinical trial, only patients containing nonmutated K-RAS genes benefit from treatment with EGFR inhibitors (Karapetis et al., 2008) . This dogma, however, might not apply to PDAC tumors. Although EGFR mutations have been found in a very small percentage (<3%) of human pancreatic cancers, they can coexist with K-RAS mutations (Oliveira-Cunha et al., 2012) . Moreover, as illustrated in this study, initiation of K-Ras oncogene-driven PanIN lesions and PDAC is absolutely dependent on EGFR signaling. This requirement is not abrogated even in the absence of the p16/p19 tumor suppressors, indicating that the absolute requirement for EGFR signaling in not involved in overcoming senescence. Only ablation of p53 overrules this requirement. Yet, neoplastic lesions lacking p53 take significantly longer to develop in the absence of EGFRs. Ongoing efforts to establish the mutational spectra of mouse PDAC exomic sequences might help us to identify those additional pathways activated by loss of p53.
Pancreatic injury results in the immediate induction of EGFR expression in acinar cells, leading to activation of the PI3K/ AKT and STAT3 signaling pathways. EGFR expression, along with activation of AKT and STAT3, is maintained during PanIN progression to PDAC and only becomes attenuated in poorly differentiated glands of advanced PDAC tumors. The EGFR is also expressed in human biopsies obtained from patients suffering from pancreatitis and PDAC tumors, thus supporting the concept that GEM models faithfully reproduce PDAC development in an experimental setting. Previous studies have shown that overexpression of TGFa in the presence of a resident KRas G12D oncogene accelerated progression of PanIN lesions to metastatic cancer and led to the development of cystic papillary lesions that resembled human intraductal papillary mucinous neoplasms (IPMN) (Siveke et al., 2007) . These observations, taken together, suggest that upregulated expression of EGFRs leading to the activation of the PI3K/AKT and STAT3 pathways might be one of the early responses that predispose acinar cells to undergo neoplastic changes upon activation of K-Ras oncogenes. It is interesting to note that in acinar cells, activation of the PI3K/AKT pathway is mediated by induction of EGFRs and not by the resident K-Ras oncogenes. These observations may explain why, in spite of the presence of K-Ras oncogenes, EGFR signaling is essential to induce neoplastic lesions in pancreatic acinar cells.
Current GEM models of PDAC do not allow target ablation in existing tumors. Yet, our results demonstrating that expression of EGFRs are essential for the proliferation of tumor cell explants strongly suggest that EGFRs signaling is essential beyond the early stages of tumor development. Indeed, knockdown or pharmacological inhibition of EGFRs blocked proliferation of certain human pancreatic tumor cells lines. Likewise, EGFR inhibitors have been shown to limit progression of pancreatic lesions in mouse xenograft models (Ng et al., 2002; Durkin et al., 2006) as well as in K-Ras oncogene-driven GEM models (Mohammed et al., 2010;  
Stat3 shRNA
ElasK-Ras G12V Figure 7 . Loss of p53 Activates STAT3 and PI3K Pathways PDAC cell explants derived from tumors present in mice with the indicated genotypes were treated with the indicated inhibitor(s) or infected with lentiviral vectors expressing two independent shRNA against Stat3 (solid and gray circles). Control cells were either left untreated or infected with a shRNA control (open circles). Erlotinib was used at a final concentration of 50 mM, a concentration that corresponds with the average IC 90 for these cell explants. ETP-46992, a selective PI3Kp110a and p110d inhibitor, was used at a final concentration of 20 mM, a concentration that corresponds to the average IC 90 for these tumor explants. Each graph represents the average of two experiments carried out with two independent cell explants. Each sample was carried out in triplicate. Errors bars mean SD. See also Figure S6 .
Finally, our results using genetic as well as pharmacologic approaches, illustrate that blocking EGFR signaling only produces limited therapeutic benefit in the context of p53 inactivation, a mutation present in most human PDAC tumors. Availability of tumor cells lacking EGFRs and p53 has allowed us to demonstrate a synergistic activity between PI3K inhibitors and attenuation of STAT3 expression. These observations suggest that loss of TP53 might ''reactivate'' the PI3K/AKT and STAT3 signaling pathways by mechanisms independent of EGFR in human tumors. Further support for a key role of the EGFR/ PI3K/AKT axis in PDAC development comes from preliminary studies in which ablation of the Pten tumor suppressor locus in ElasK-Ras G12V ;Egfr lox/lox mice leads to efficient tumor development (C.N., I.H., C.G., and M.B., unpublished observations). Recent observations regarding a limited but significant tumor inhibitory effect by inhibitors of the Notch pathway (Plentz et al., 2009; Cook et al., 2012) may open the door to design therapeutic strategies in combination with PI3K and STAT3 inhibitors. Yet, to induce complete regression of aggressive PDAC tumors it will be necessary to unveil additional signaling pathways amenable to pharmacological inhibition. Recent progress in overcoming the stromal barrier characteristic of PDAC tumors (Olive et al., 2009; Von Hoff et al., 2011; Frese et al., 2012; Jacobetz et al., 2012; Provenzano et al., 2012) should facilitate testing these drug combinations in relevant GEM models of pancreatic cancer as a preliminary step prior to their use in a clinical setting.
EXPERIMENTAL PROCEDURES Mice
The ElasK-Ras G12V strain has been previously described (Guerra et al., 2007) .
In these mice, the Elas-tTA/tetO-Cre transgenes drive expression of the bacterial Cre recombinase from the Elastase promoter under the negative control of doxycycline (Tet-off system). Egfr alleles were treated 3 days per week for 2 weeks with 4OHT (0.5 mg/ml in oil) starting at P21. Erlotinib treatment was carried out in 6-week-old ElasKRas G12V ;p53 lox/lox mice by oral gavage (100 mg/Kg in 0.5% methylcellulose with 0.1% Tween80) for 4 weeks. Control mice received the same treatment without Erlotinib.
Histopathology and Immunohistochemistry
Specimens were fixed in 10% buffered formalin and embedded in paraffin. For histopathological analysis, pancreata were serially sectioned (3 mm thick) and every ten sections stained with hematoxylin and eosin (H&E). Remaining sections were kept for immunohistochemical studies with b-catenin (1:750, goat polyclonal; Santa Cruz Biotechnology, Sc-1496), pAKT (pS473) (1:175, rabbit monoclonal EP2109Y; Epitomics 2118-1), EGFR (1:100, rabbit monoclonal; Epitomics 1902-1), SPC (1:175, rabbit polyclonal; Millipore, AB3786), and pSTAT3 (Tyr705) (1:100, rabbit monoclonal D3A7; Cell Signaling Technology, 9145) antibodies. Following incubation with the primary antibodies, positive cells were visualized using 3,3-diaminobenzidine tetrahydrochloride plus (DAB+) as a chromogen. For human samples (see below), immunostaining for EGFRs was preformed as described above.
PDAC Cell Explants
To generate mouse PDAC explants, freshly isolated tumors were minced with sterile razor blades, digested with collagenase P (1.5 mg/ml) in Hanks' balanced salt solution (HBSS) for 30 min at 37 C, and cultured in DMEM with 10% of fetal bovine serum (FBS). After 48 hr, media was supplemented with Geneticin (75 mg/ml) to select for K-Ras G12V expressing cells. All studies were done on cells cultivated for less than ten passages. Their corresponding genotypes were verified by PCR analysis.
Cell Culture and Inhibitor Treatments
Mouse embryonic fibroblasts (MEFs) were isolated from E13.5 embryos and propagated according to standard 3T3 protocols. Human tumor cell lines PANC1, MIAPaCa-2, SKPC, T3M4, were purchased from ATCC. BxPc3 was kindly provided by M. Hidalgo (CNIO). AsPc1, CFPAC, and IMIMPC-2 by F.X. Real (CNIO). These cell lines as well as the PDAC explants were seeded in 96-well plates at a density of 1,000 cells/well or 300 cells/well, respectively, and incubated for 24 hr in DMEM media supplemented with 10% FBS, 2 mM L-glutamine, 50 U/ml penicillin, and 50 mg/ml streptomycin (GIBCO-Invitrogen) before adding the corresponding inhibitor. Inhibitors, including EGFR inhibitor Erlotinib (LC laboratories), MEK inhibitor PD0325901 (Pfizer), and PI3K inhibitor ETP-46992 (CNIO) (Martínez Gonzá lez et al., 2012) , were dissolved in DMSO to yield the appropriate final concentrations. Three sets of control wells were included on each plate, containing either medium without drug or medium with the same concentration of DMSO. Cells were exposed to inhibitors for 10 to 14 days. Fresh drug was added every 2 days. For shRNA knockdown assays, human or mouse tumor cells were infected with MISSION shRNAs (Sigma) directed against human EGFR (TRC0000121206 and TRC0000121203), mouse Egfr (TRCN0000055218 and TRCN0000055221), and mouse Stat3 (TRCN0000071454 and TRCN0000071456) sequences. Non-Target shRNA Control vector (SHC002, Sigma) was used as a negative control. Cells were selected with puromycin (2 mg/ml) for 5 days before seeding and maintained in DMEM media supplemented with 10% FBS and puromycin. Proliferation rates were determined by the (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Roche 
